It seems to me appropriate to review the management and therapy of tuberculosis as Dr Ellman knew them 20 years ago, and the changes which have taken place, some of which were then almost inconceivable.
The mid-1950s is an appropriate starting point for such a review, since at that time therapy was so successful in a few outstanding centres that it was tempting to think that it could not be bettered. Indeed, there was a danger that the then current practices would neither be changed appreciably nor even submitted to further critical scientific investigation. It is fortunate indeed that the pressing needs of the developing countries compelled a continuing search for effective methods of therapy that were more simple and so more readily available and more easily applied. The relatively recent introduction of rifampicin has also contributed to developments that have necessitated a complete reevaluation of chemotherapy, a process which is likely to continue for a number of years. It must be stated at the outset that tuberculosis remains a major health problem. The number of infectious cases in the world, a high proportion in the developing countries, is estimated to be in the range of 15-20 million and the reported annual incidence of pulmonary tuberculosis in some areas of Africa, Asia and Oceania is 200-350 cases per 100 000 inhabitants (WHO 1974) . This report also reminds us that even in technically advanced countries where tuberculosis 'is considered rare it often causes more deaths than all other notifiable infectious diseases combined'. Further, with over 8000 cases diagnosed in England and Wales in 1974, and a high incidence among immigrants, tuberculosis will remain a therapeutic problem in Britain for many years to come.
MANAGEMENT OF PATIENTS IN THE MID-1950s
In the mid-1950s therapy with streptomycin, paraaminosalicylic acid (PAS) and isoniazid was, beyond all question, highly effective and the era of the so-called '100 %-successful therapy' had arrived. However: (1) The regimen was given for two years or more. (2) Doses were divided into 2-4 per day. (3) The patient spent many months in sanatorium, with careful adherence to the classical sanatorium regime, including a nutritious diet, bed rest and fresh air in rural surroundings. (4) Patients had regular monthly postero-anterior radiographs and several tomographic series. (5) Smear and culture examination of the sputum was performed monthly. (6) Sensitivity tests were undertaken as a routine, before treatment began and on all positive cultures during treatment, chemotherapy being adjusted if a resistant strain was grown, and on all cultures in patients who relapsed bacteriologically. (7) There were also many indications for surgery, it being the heyday of resection. (8) Finally, even when the chemotherapy was stopped there was a prolonged and regular follow-up, perhaps monthly, extending to 3-6-monthly, for several years before the patient was pronounced cured.
Thus, although treatment in expert hands was highly effective it made major demands on the patient and his family (interfering with domestic, social and working life), on the supervisory staff and on health service resources. Tuberculosis was one of the most expensive diseases to treat. Over the last 20 years the various components oftherapy have been studied, particularly in controlled clinical trials and in the developing countries. Remarkable and quite unpredictable simplification, of major importance in cost-benefit terms, has resulted. Comparing costs in 1954/55 and 1974/75 (adjusted), the current annual saving to the community in Britain is at a conservative estimate £275 million (Teeling-Smith 1976, personal communication) , much of it resulting from the application of research findings. SUBSEQUENT CHANGES IN MANAGEMENT (1) Duration ofchemotherapy: The minimum duration of chemotherapy for sputum-positive patients was two years, but indefinitely prolonged chemotherapy and chemotherapy for life also had advocates (Lancet 1953) . A survey in Scotland of the therapy of a random sample ofcases newly notified in 1968 has revealed that the average duration of chemotherapy for the bacteriologically confirmed patients was 22.8 months and for the negative cases 19.1 months (Heffernan et al. 1976) . How far removed this is from modern short-course chemotherapy, which I review later.
(2) Number ofdoses a day: Oral medicaments were usually given in 2-4 doses a day on the assumption that it was essential to maintain minimal inhibitory concentrations (MICs) of the drugs in the blood throughout the 24 hours. However, this was found to be unnecessary in a study in the Chemotherapy Centre, Madras, for 400 mg a day of isoniazid alone in one dose proved somewhat more effective than two doses of 200 mg, even though the latter maintained a continuous MIC and the former did not (Gangadharam et al. 1961 Chemotherapy, Prague 1973 which compared ambulation with bed rest in sanatorium (2 studies) or treatment at home with treatment in sanatorium (7 studies) or normal work with rest in bed (1 study). Not one has demonstrated benefits from rest or hospitalization. In 8 studies all the cases were bacteriologically positive. In 5 far-advanced disease was studied in developing countries where the accommodation, diet and climate were unfavourable and the occupations usually arduous. Even by the early 1960s the components of the classical sanatorium regime had been scientifically debunked (Ramakrishnan et al. 1961 , Ramakrishnan et al. 1966 . The main indication for hospital admission is now for complications. Striking confirmation has been provided by the effectiveness of ambulatory chemotherapy for the treatment of spinal disease (Medical Research Council 1973a ,b, 1976 . (The evidence that, and the reasons why, ambulatory domiciliary therapy of the patients does not expose their close family contacts to special risk, even when the living conditions are most unfavourable, have been reviewed elsewhere (Fox 1968b , Johnston & Wildrick 1974 .) (4) Regular monthly radiography: Regular monthly radiography was usual, but it has become increasingly recognized over the years that the changes in the radiographic appearances are most uninformative, and may be positively misleading (Fox 1962b, Dawson et al. 1966) . The interpretation of the significance of residual cavitation virtually depends on knowing whether the patient is still excreting bacilli. Hence the relegation of radiography to a minor role.
(5) Regular monthly smear and culture: Smear and culture examination remains the most valuable method of assessing therapy. It has, however, been increasingly appreciated that the examinations in the early months are by no means essential, since some patients only convert to negativity after a few months' chemotherapy and contrarywise the early disappearance of bacilli does not mean that subsequent relapse may not occur. In standard chemotherapy assessments at 5-6 months and subsequently are the most informative, and in short course chemotherapy the assessments towards the end of the course. Although culture adds to the precision of the assessments (including identifying smear positive but culture negative specimens) and may sometimes detect relapse early, smear examination is a basic examination in patients smear positive on admission.
(6) Sensitivity tests: Sensitivity tests before and during treatment were regarded as essential in management, the regimen being changed if a resistant strain was found. (a) Initial resistance: There was much evidence in the literature, which was largely overlooked, that if patients with pretreatment resistant strains continued on their regimen unchanged they often had a satisfactory response (Fox 1968a Kong/BMRC 1972 . Two main policies were compared, namely, (1) treatment with the standard regimen of streptomycin plus isoniazid plus PAS, without reference to the pretreatment sensitivity tests, and (2) the then classical management, treatment commencing with the same regimen, other drugs being substituted if initial resistance were found in the sensitivity tests. Even although 33 % of the patients on the first policy had initial drug resistance to one or more drugs (18% to 1, 10% to 2 and 5% to all 3), the proportion of patients whose chemotherapy failed on account of pretreatment drug resistance was small as assessed up to 3 years, the implementation of both policies achieving the same level of success. A striking observation, however, was that a more important cause of failure than initial resistance was the patients' irregularity in self-administering their oral drug in the continuation phase. It was possible to estimate that with the same regimen in Britain, where the prevalence of primary resistance is 4-5 %, about 1 in 150 sputum-positive patients would remain bacteriologically positive if treatment were given without reference to initial drug resistance, and so require a retreatment regimen. Moreover, the introduction of rifampicin, ethambutol and pyrazinamide into primary chemotherapy, drugs to which primary resistance is very uncommon, minimizes even further the effect of initial resistance.
There is much other evidence that the key factor in the failure of highly potent regimens under programme conditions, especially in developing countries, is irregularity in self-administration of medicaments in patients with fully sensitive organisms (Fox 1972) , Evans et al. 1969 ). In the 1968 Scottish survey only 6 of 770 newly notified patients were, in fact, submitted to surgery (Heffernan et al. 1976) . (8 Summarizing, the modern view of management is that the factors which are vital to the outcome of treatment are the provision of effective regimens organized and supervised in ways that ensure that the patient cooperates in treatment, the assessment of success or failure of a regimen being bacteriological.
SHORT-COURSE CHEMOTHERAPY
In the 1960s it became increasingly evident to my group that long-term chemotherapy with the socalled 1000% effective regimens was beyond the organizational and financial resources of nearly all the developing countries. Furthermore, service programmes based on the more recently introduced intermittent, fully supervised regimens also presented difficulties. In consequence the success rate achieved by the routine treatment services, and also in studies conducted in similar conditions, with 100 % effective regimens could fall to levels of the order of 50% (Fox 1972) . We therefore came to realize that ifwe were able to find a 6-month regimen that could cure, say, 85 % or more of the patients, although being far from perfect chemotherapy, it might well prove substantially superior under programme conditions than the standard long-term regimens. In fact, there was already evidence, summarized elsewhere (Fox & Mitchison 1975) to suggest that 6-month regimens might well be highly effective. Further, although rifampicin-isoniazid regimens were likely to be effective, there was a real possibility that regimens not including rifampicin would also be effective, particularly pyrazinamide in combination with streptomycin and isoniazid (McDermott et al. 1954 , US Public Health Service 1959 , Matthews 1960 , McCune et al. 1966 , Sunahara 1970 . This led us to set up, in association with our colleagues in East Africa, in patients with newly-diagnosed, extensive, smear-positive disease, the first short-course chemotherapy study ever undertaken.
First East African Study
The four 6-month regimens and the bacteriological relapse rates in patients with drug-sensitive infections before treatment are shown in Table 1 . All the regimens were, for all practical purposes, uniformly successful at 6 months, as we had expected from the known efficacy of the combination of streptomycin plus isoniazid (Fox 1968a) . The vital issue, however, was the bacteriological relapse rates. In a two-year period of follow up these were low in the rifampicin (SHR) and pyrazinamide (SHZ) regimens, especially the former, but much higher in the thiacetazone (SHT) and two-drug (SH) regimen. Moreover, there are two further important points about the relapses, which we have subsequently confirmed in other studies, both in East Africa and in Hong Kong. First, the great majority occur in the first 6 months (indeed, most in the first 3 months) after stopping chemotherapy. Secondly, nearly all occur with drug-sensitive organisms, irrespective of whether the regimens have high or low relapse rates. It is thus evident that the patients who suffer a bacteriological relapse have in their lungs residual sensitive organisms at the time the chemotherapy is stopped and that the multiplication of these organisms usually begins shortly after, so that they reappear in the sputum, usually within a few Table 1 months. Thus, failure is not due to the emergence of drug resistance and success means either the complete elimination of bacilli in the lesions or their reduction to such small numbers that the host resistance is thereafter-capable of containing them indefinitely.
Two immediate questions arise: (1) Is there a risk of late relapse? (2) Are the organisms in patients who relapse drug-sensitive in clinical practice as well as in laboratory tests?
(1) We are studying the relapse rate up to 5 years for the rifampicin regimen. Up to 4 years there have been no further relapses in this series; in fact, the last relapse occurred at 16 months, that is, 10 months after the 6-month course was terminated. These longer-term findings are wholly encouraging. It merits emphasis that in developing countries such as East Africa, if sporadic late 'relapses' arise, it does not follow that these are genuine relapses. With the high risks of infection that exist in such communities, the cause might well be a reinfection.
(2) It can be concluded from studies in East Africa and Hong Kong that patients who relapse with sensitive strains, as tested in the laboratory, respond to retreatment with standard regimens, which include the major drugs received in their short-course regimens (Hong Kong/East African/ BMRC 1976 Table 2 ). The control regimen was streptomycin, isoniazid and rifampicin daily (SHR), the most effective regimen in the first study. Isoniazid plus rifampicin daily (HR) was studied to see what contribution, if any, the streptomycin was making to the effectiveness of the triple regimen. Isoniazid plus rifampicin according to the first hypothesis can be regarded as two bactericidal drugs. By the other hypothesis it is a combination of 2 potent drugs, one, rifampicin, having a special sterilizing action. We also explored the role of an initial intensive phase with the 4 potent drugs, streptomycin, isoniazid, rifampicin and pyrazinamide, followed in the third regimen by the twice-weekly regimen of streptomycin, isoniazid and pyrazinamide. The latter, according to the first hypothesis, contains 2 bactericidal drugs in the continuation phase (isoniazid one, and streptomycin plus pyrazinamide the other) and by the second hypothesis the special sterilizing drug, pyrazinamide. In the fourth regimen the standard East African continuation combination of thiacetazone plus isoniazid (a single bactericidal drug) was given, as it is cheap and is highly effective in standard duration chemotherapy.
The results at 30 months demonstrated that although isoniazid plus rifampicin had a low relapse rate, the streptomycin made a small but statistically-significant difference in the triple regimen (P=0.05). However, the initial intensive phase of4 drugs, whether followed by thiacetazone plus isoniazid or by the intermittent regimen, proved effective, although the inferiority of the former when compared with the triple (SHR) regimen just achieved statistical significance. In the first East African study streptomycin plus isoniazid plus thiacetazone daily for 6 months was relatively ineffective. Thus, thiacetazone plus isoniazid in the second study can have played only a minor role, the success of the regimen being largely dependent on the 4-drug initial intensive phase. Since the combination of streptomycin plus isoniazid plus pyrazinamide has the same order of effectiveness whether given twice a week or daily (Hong Kong/BMRC 1975) , and the twice-weekly continuation regimen was little, if any, better than the thiacetazone plus isoniazid regimen, it again emphasizes the role of the 4-drug initial intensive phase.
Role ofIsoniazid in the Continuation Phase It is of interest to consider whether the contribution of the continuation phase with thiacetazone plus isoniazid owes anything to the thiacetazone or whether it is dependent entirely on the isoniazid. This latter may well be the case since in the first East African study (Table 1) Table 3 Results of a study of twice weekly regimens for 9 months in Roumania ( Anastasatu 1976, personal numbers and the exclusion of a few patients from the continuation phase because they were still bacteriologically positive at the end of the intensive phase (that is, the patients most likely to have been at risk ofbacteriological failure or relapse), this study is ofobvious importance from the point ofview ofthe mechanisms of short-course chemotherapy, suggesting that, after the initial intensive phase with 3 drugs, including rifampicin, both isoniazid alone and rifampicin alone were effective in the continuation phase.
The results (Table 3 ) of a randomized study of 9-month regimens undertaken by Anastasatu (1976) are also relevant. After an initial phase of 3 months with rifampicin and isoniazid twice a week in 1 regimen and with streptomycin, isoniazid and ethambutol twice a week in another, either ethambutol plus isoniazid or streptomycin plus isoniazid twice a week was given in the continuation phase, which lasted for 6 months. Bacteriological failures whilst on chemotherapy were few on both regimens and subsequent bacteriological relapses were infrequent on the rifampicin regimen in a 12-month period of follow up. Again the question arises whether the twice-weekly isoniazid in the continuation phase, without the ethambutol or without the streptomycin, might have been equally effective, especially in the promising rifampicin regimen.
It is obviously important to elucidate the role of monotherapy with isoniazid in the continuation phase of short-course chemotherapy, and to my mind the findings from the second East African study and the studies of Montaner and Anastasatu all suggest that isoniazid has a sterilizing role, even although the animal experimental evidence would suggest that it is less active in this respect than rifampicin or pyrazinamide.
It should be noted that the study of Anastasatu (1976) provides some evidence that twice-weekly chemotherapy from the very start oftreatment can, as we had predicted from the Madras study (Fig 1) , form effective short-course combinations. This study confirms the findings of an investigation in Hong Kong (Hong Kong/BMRC 1975) in which streptomycin, isoniazid and pyrazinamide given 3 times a week for 9 months was an effective regimen, and this holds up to 24 months. When the 3 drugs were given twice weekly they were only marginally less effective, and this was because of the emergence of drug-resistant strains in a few patients, who failed bacteriologically on this account.
The studies of Brouet and his colleagues (Roussel 1975) in France and of the British Thoracic and Tuberculosis Association (Angel et al. 1975 ) in this country (Table 4) have consolidated the evidence on short-course chemotherapy. Rifampicin plus isoniazid daily for 9 months supplemented either with streptomycin or ethambutol for 2 or 3 months is uniformly effective. However (Table 2) , since streptomycin daily for 6 months (East African/British MRC 1974b , the first 2 months being the best time to compare the relative speeds with which regimens produce culture negativity. Whereas the potent 3-drug regimen of streptomycin, isoniazid and rifampicin produced a culture negativity rate of 70%, the addition of pyrazinamide to this 3-drug regimen increased the culture negativity rate at 2 months to 82 %, a notable and statistically significant difference (P=0.006). Thus, pyrazinamide can exert a measurable effect over and above that of the potent 3-drug combination.
The second issue concerning pyrazinamide which merits consideration is its toxicity. When it was given daily in high dosage with isoniazid in primary chemotherapy in the USA it was reported to be hepatotoxic and its use was, for all practical purposes, abandoned. In Britain, as in most other countries, pyrazinamide has only been used in combination with the toxic drugs ethionamide and cycloserine in patients with an unsatisfactory response, most of whom are middle-aged or elderly, and who have failed on primary chemotherapy because of drug toxicity and/or poor cooperation. These circumstances make it difficult to identify which adverse reactions are due to pyrazinamide. Moreover, the interpretation of abnormal hepatic function tests has added to the confusion and many of the reports of hepatic toxicity in the literature rested solely on these. We had experience of the use of pyrazinamide in moderate dosage daily and in higher intermittent doses in varying combinations with the standard drugs, streptomycin, isoniazid and PAS (Fox & Mitchison 1975) , and we were impressed by the convenience and low toxicity of the regimens. In the more recent studies with which we have been associated in East Africa and Hong Kong, special care has been taken in investigating the toxicity of pyrazinamide-containing regimens and the possible contribution that pyrazinamide may have had. Indeed, in designing studies we now regularly include regimens that will enable the level of pyrazinamide toxicity to be measured. For example, in the study in Hong Kong which included streptomycin, isoniazid and pyrazinamide daily for 6 months, a 6-month regimen of streptomycin, isoniazid and PAS daily was also added to permit an accurate evaluation of the contribution that pyrazinamide made to the toxicity of the regimen (Hong Kong/BMRC 1976) . A current study in Hong Kong also contains a direct comparison of a pyrazinamide-and a nonpyrazinamide-containing regimen.
Minimum Duration of Short-course Chemotherapy We have seen that 6-month regimens, notably streptomycin, isoniazid and rifampicin daily, can come close to being 100 % effective with no failures during chemotherapy and with very low relapse rates (Tables 1 and 2) and can equal the level of success achieved under programme conditions by classical primary chemotherapy with streptomycin, isoniazid and PAS followed by isoniazid and PAS even in technically-advanced countries with a highly organized and efficient service (Heffernan et al. 1976) . Can, however, the duration of chemotherapy be reduced even further? Kreis et al. (1975) , in a pilot investigation, studied streptomycin, isoniazid and rifampicin, either giving all 3 drugs daily for 3 months or giving the streptomycin daily and the other 2 drugs 3 times a week. The relapse rates were similar for both regimens, 15 % and 11 %. Thus, when the duration of chemotherapy was reduced from 6 months to 3 months there was a relatively small decline in the efficacy of the triple combination. It is virtually certain that the 3-month regimen would be strengthened by the addition of pyrazinamide and by its prolongation for perhaps only a few more weeks. Thus, the prospects for courses of chemotherapy even shorter than 6 months are excellent.
In most countries a high proportion (often much more than 50%) of the patients brought under Kong/BMRC 1972 . In the two East African short course studies (East African/BMRC 1972 , 1974a ,b, 1976 , 90.9% of patients admitted had fully sensitive organisms, 6.2 % an isoniazid-resistant strain, 1.7 % a streptomycin-resistant strain and 1.2% a strain resistant to both drugs. The estimated failure rates per 100 patients for the 5 effective regimens in East Africa are given in Table 5 separately for patients with fully sensitive strains and for the full population, that is whether the strains were sensitive or resistant. The failure rates for the latter were increased by 2 % in 4 of the regimens and by 1 % in the fifth.
In the short course study in Hong Kong (Hong Kong/BMRC 1975) , 21.2 % of patients had initial drug resistance: 4.8 % to isoniazid, 8.9 % to streptomycin and 7.5 % to both drugs. The estimated failure rates for the 3 regimens of streptomycin, isoniazid and pyrazinamide (daily, 3 times a week and twice a week) for 9 months (Table 5) ranged from 5 % to 11 % for the sensitive population and from 130% to 18,% for the full population, an increase of 7 % or 8 %. These rates refer to an area with exceptionally high levels of initial resistance, including a substantial proportion with double drug resistance, which suggests that the initial resistance was often acquired (and so less likely to respond to the relevant drugs than primary resistance). Also they apply to regimens which did not include rifampicin.
When initial resistance to standard drugs is frequent there are likely to be benefits in using regimens that contain both rifampicin and pyrazinamide, in part because initial resistance to them is very infrequent and in part because of their special sterilizing role. There is, in fact, evidence that pyrazinamide has a sterilizing role whether the patient's strain is initially fully sensitive, or resistant to other drugs in the regimen. Thus, in the Hong Kong (1975) 
